Literature DB >> 29730660

Perinatal Outcome and Long-Term Neurodevelopment after Intracranial Haemorrhage due to Fetal and Neonatal Alloimmune Thrombocytopenia.

Dian Winkelhorst1, Marije M Kamphuis2, Sylke J Steggerda3, Monique Rijken3, Dick Oepkes2, Enrico Lopriore3, Jeanine M M van Klink3.   

Abstract

OBJECTIVES: To evaluate the perinatal and long-term neurodevelopmental outcome in a cohort of children with intracranial haemorrhage (ICH) due to fetal and neonatal alloimmune thrombocytopenia (FNAIT) and to clearly outline the burden of this disease. SUBJECTS AND METHODS: We performed an observational cohort study and included all consecutive cases of ICH caused by FNAIT from 1993 to 2015 at Leiden University Medical Centre. Neurological, motor, and cognitive development were assessed at a minimum age of 1 year. The primary outcome was adverse outcome, defined as perinatal death or severe neurodevelopmental impairment (NDI). Severe NDI was defined as any of the following: cerebral palsy (Gross Motor Function Classification System [GMFCS] level ≥II), bilateral deafness, blindness, or severe motor and/or cognitive developmental delay (<-2 SD).
RESULTS: In total, 21 cases of ICH due to FNAIT were included in the study. The perinatal mortality rate was 10/21 (48%). Long-term outcome was assessed in 10 children (n = 1 lost to follow-up). Severe and moderate NDI were diagnosed in 6/10 (60%) and 1/10 (10%) of the surviving children. The overall adverse outcome, including perinatal mortality or severe NDI, was 16/20 (80%).
CONCLUSIONS: The risk of perinatal death or severe NDI in children with ICH due to FNAIT is high. Only screening and effective preventive treatment can avoid this burden.
© 2018 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Fetal and neonatal alloimmune thrombocytopenia; Intracranial haemorrhage; Long-term outcome; Neurodevelopment

Mesh:

Year:  2018        PMID: 29730660      PMCID: PMC6482979          DOI: 10.1159/000488280

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  5 in total

1.  Characterization of glycoprotein IIb/IIIa-specific alloantibodies induced by cross-strain platelet immunization in mice.

Authors:  Daniel W Bougie; Jessica Sutton; Richard H Aster
Journal:  Transfusion       Date:  2021-01-22       Impact factor: 3.157

2.  Clinical characteristics of human platelet antigen (HPA)-1a and HPA-5b alloimmunised pregnancies and the association between platelet HPA-5b antibodies and symptomatic fetal neonatal alloimmune thrombocytopenia.

Authors:  Thijs W de Vos; Leendert Porcelijn; Suzanne Hofstede-van Egmond; Eva Pajkrt; Dick Oepkes; Enrico Lopriore; C Ellen van der Schoot; Dian Winkelhorst; Masja de Haas
Journal:  Br J Haematol       Date:  2021-08-16       Impact factor: 8.615

3.  Outcome Trajectories after Primary Perinatal Hemorrhagic Stroke.

Authors:  Giulia S Porcari; Lori C Jordan; Rebecca N Ichord; Daniel J Licht; Sabrina E Smith; Lauren A Beslow
Journal:  Pediatr Neurol       Date:  2019-12-09       Impact factor: 3.372

4.  HIP (HPA-screening in pregnancy) study: protocol of a nationwide, prospective and observational study to assess incidence and natural history of fetal/neonatal alloimmune thrombocytopenia and identifying pregnancies at risk.

Authors:  C Ellen van der Schoot; Masja de Haas; Dian Winkelhorst; Thijs W de Vos; Marije M Kamphuis; Leendert Porcelijn; Enrico Lopriore; Dick Oepkes
Journal:  BMJ Open       Date:  2020-07-20       Impact factor: 2.692

5.  Placental Complement Activation in Fetal and Neonatal Alloimmune Thrombocytopenia: An Observational Study.

Authors:  Thijs W de Vos; Dian Winkelhorst; Hans J Baelde; Kyra L Dijkstra; Rianne D M van Bergen; Lotte E van der Meeren; Peter G J Nikkels; Leendert Porcelijn; C Ellen van der Schoot; Gestur Vidarsson; Michael Eikmans; Rick Kapur; Carin van der Keur; Leendert A Trouw; Dick Oepkes; Enrico Lopriore; Marie-Louise P van der Hoorn; Manon Bos; Masja de Haas
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.